Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

Delayed Data
As of Dec 08
 +0.22 / +1.31%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing novel predictive and personalized medicines and prognostic medicine tests. It operates through the following segments: Research, Molecular Diagnostics and Companion Diagnostics. The Research segment focuses on the discovery of genes related to major common diseases and includes corporate services such as finance, human resources, legal and information technology. The Molecular Diagnostics segment provides testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The Companion Diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.

Contact Information

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City Utah 84108
P:(801) 584-3600
Investor Relations:
(801) 584-1143



Other institutional78.25%
Mutual fund holders50.20%
Individual stakeholders3.67%

Top Executives

Mark C. CaponePresident, Chief Executive Officer & Director
Gary A. KingExecutive Vice President-International Operations
R. Bryan RiggsbeeChief Financial Officer, Treasurer & Executive VP
Robert Gardner HarrisonChief Information Officer
Jerry S. LanchburyChief Scientific Officer